CollPlant Biotechnologies Ltd Ordinary Shares New CLGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-
CollPlant Issues Letter to Shareholders
-
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
-
CollPlant Biotechnologies Launches Redesigned Corporate Website
-
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS
Trading Information
- Previous Close Price
- $0.37
- Day Range
- $0.37–0.38
- 52-Week Range
- $0.27–3.23
- Bid/Ask
- $0.37 / $0.38
- Shares Outstanding
- 14.42M
- Market Cap
- $5.34M
- Volume/Avg
- 17,151 / 80,217
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.19
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 39
- Website
- https://www.collplant.com
Valuation
|
Metric
|
CLGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.10 |
Price/Sales | 12.19 |
Price/Cash Flow | — |
Price/Earnings
CLGN
Financial Strength
|
Metric
|
CLGN
|
|---|---|
Quick Ratio | 1.84 |
Current Ratio | 2.27 |
Interest Coverage | — |
Quick Ratio
CLGN
Profitability
|
Metric
|
CLGN
|
|---|---|
Return on Assets (Normalized) | −89.79% |
Return on Equity (Normalized) | −136.55% |
Return on Invested Capital (Normalized) | −105.41% |
Return on Assets
CLGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Zypzlyzlf | Gnrcwj | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yqzrbzgsm | Xxpvb | $67B | |||
| argenx SE ADR
ARGX
| Hxdfnktc | Dcpb | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wqlnwydr | Tzzgjdf | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Xhjhpfyr | Ztglfpd | $25B | |||
| BioNTech SE ADR
BNTX
| Drkpbjv | Crtns | $22B | |||
| Incyte Corp
INCY
| Wttqkjxwv | Vcrc | $20B | |||
| Moderna Inc
MRNA
| Zxgkhdz | Fkp | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Zpfbbjycp | Jkpbn | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Vwkpglgg | Zlt | $13B |
United States